Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol

This article was originally published in PharmAsia News

Executive Summary

Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds

You may also be interested in...

Aslan Gets Singapore Nod For Initial Trial Of RA Candidate From Spain’s Almirall

Aslan Pharmaceuticals received approval for a Phase I clinical trial of a rheumatoid arthritis DHODH inhibitor by Singapore’s Health Sciences Authority and will work with CRO Quintiles at Changi General Hospital.

ASLAN Gets Global Rights To Almirall RA Candidate, Third Deal In Less Than A Year For Singapore Startup

ASLAN Pharmaceuticals branches out from oncology for its third compound, but the formula is the same: in-license for Asia and find a CRO.

AstraZeneca Licenses Global Rights To Oncology Compound From China’s Hutchison

AstraZeneca pays $20 million up front to license Hutchison’s Phase I-ready compound in another sign that the U.K. pharma has its eyes set firmly on China.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts